Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S231500, C514S235500, C514S255030, C514S256000, C514S269000, C514S277000, C514S278000, C514S316000, C514S317000, C514S320000, C514S321000, C514S326000, C514S336000, C514S357000, C514S365000, C514S366000, C514S374000, C514S375000, C514S378000, C514S397000, C514S398000, C514S399000, C514S432000, C514S451000, C514S601000, C514S602000, C514S603000, C514S645000, C514S709000, C546S193000, C546S194000, C546S197000, C546S199000, C546S207000, C546S216000, C546S221000, C546S229000, C546S321000
Reexamination Certificate
active
07115632
ABSTRACT:
A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity. A contemplated compound corresponds in structure to the formulawherein W and the R groups are defined elsewhere.
REFERENCES:
patent: 4148801 (1979-04-01), Santilli et al.
patent: 4595700 (1986-06-01), Donald et al.
patent: 5103014 (1992-04-01), Musser et al.
patent: 5424279 (1995-06-01), Sugai et al.
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5506242 (1996-04-01), MacPherson et al.
patent: 5552419 (1996-09-01), MacPherson et al.
patent: 5646167 (1997-07-01), MacPherson et al.
patent: 5932595 (1999-08-01), Bender
patent: 6013649 (2000-01-01), Freskos et al.
patent: 6118001 (2000-09-01), Owen et al.
patent: 6380258 (2002-04-01), Bedell et al.
patent: 6462073 (2002-10-01), Venkatesan et al.
patent: 6465468 (2002-10-01), Baxter
patent: 6794511 (2004-09-01), Bedell et al.
patent: 3738890 (1989-05-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 994 104 (2000-04-01), None
patent: 1 081 137 (2001-03-01), None
patent: 853255 (2001-05-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 93/20047 (1993-10-01), None
patent: WO 94/02466 (1994-02-01), None
patent: WO 94/24140 (1994-10-01), None
patent: WO 95/09841 (1995-04-01), None
patent: WO 95/13289 (1995-05-01), None
patent: WO 95/29892 (1995-11-01), None
patent: WO 96/06074 (1996-02-01), None
patent: WO 96/11209 (1996-04-01), None
patent: WO 97/20824 (1997-06-01), None
patent: WO 97/24117 (1997-07-01), None
patent: WO 97/49679 (1997-12-01), None
patent: WO 98/06705 (1998-02-01), None
patent: WO 98/37877 (1998-09-01), None
patent: WO 98/38859 (1998-09-01), None
patent: WO 99/09000 (1999-02-01), None
patent: WO 99/25687 (1999-05-01), None
patent: WO 00/37107 (2000-06-01), None
patent: WO 00/46221 (2000-08-01), None
patent: WO 00/50396 (2000-08-01), None
patent: WO 00/56704 (2000-09-01), None
patent: WO 00/59874 (2000-10-01), None
patent: WO 00/69819 (2000-11-01), None
patent: WO 00/69821 (2000-11-01), None
patent: WO 01/17965 (2001-03-01), None
Cremlyn et al. “Some heterocyclic sulfonyl chlorides and derivatives” CA 96:52222 (1981).
Helland “Sulfamylbenzoic acids” CA 86:89409 (1986).
Brown, P.D., “Synthetic Inhibitors of Matrix Metalloproteinases,” inMatrix Metalloproteinases, pp. 243-261 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA (1998)).
Tang, B.L., “ADAMTS: A Novel Family of Extracellular Matrix Proteases,”Int'l Journal of Biochemistry&Cell Biology, 33 pp. 33-44 (2001).
Woessner, J.F., “The Matrix Metalloprotease Family” inMatrix Metalloproteinases, pp. 1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA (1998)).
Young, (1995) CA 123:83233.
Cramp, (1998) CA 128:208524.
Fujisawa, (1999) CA 131:73975.
Lombardino, XP-002179389—Preparation of Substituted 1,2-Benzoisothiazolin-3-one 1, 1-Dioxides(o-Benzoic Sulfimides) J. Org. Chem. vol. 36, No. 13, (1971), pp. 1843-1845.
Zawisza and Malinka, XP-002179391A Novel System: 2H-Pyrido [3,2-e]-1,2-Thiazine-1, 1-Dioxide. Synthesis and Properties of Some Derivatives, II Farmaco—Ed. Sc. vol. 41, fasc. 10,(1986) pp. 819-826.
Arranz et al., XP-001024950—Synthesis and Anti-HIV Activity of 1,1,3-Trioxo-2H, 4H-thieno[3,4-e]thiadiazines(TTDs):A New Family of HIV-1 Specific Non-Nucleoside Reverse Transcriptase Inhibitors, Bioorganic & Medicinal Chemistry 7 (1999), pp. 2811-2822.
Arranz et al., XP-002179390—Novel 1, 1,3-Trioxo-2H, 4H-thieno[3,4-e][1,2,4]thiadiazine Derivatives as Non-Nucleoside Reverse Transcriptase Inhibitors That Immunodeficiency Virus Type 1 Replication, J. Med. Chem. (1998), 41, pp. 4109-4117.
Barta et al.,Synthesis and Activity of Selective MMP Inhibitors with an Aryl Backbone, Bioorganic & Medicinal Chemistry Letters 10 (2000), pp. 2815-2817.
U.S. Appl. No. 09/728,408, filed Dec. 1, 2000, Bedell et al.
U.S. Appl. No. 09/909,227, filed Jul. 19, 2001, Barta et al.
U.S. Appl. No. 09/997,552, filed Nov. 29, 2001, Bedell et al.
Denis et al.,Matrix metalloproteinese inhibitors: Present achievements and future prospects, Invest, New Drugs, 15:175-185 (1997).
Gearing et al.,Processing of tumor necrosis factor-α precursor by metalloproteinases, Nature, 370:555-557 (1994).
Hannout et al.,Synthesis and screening of some new methyl salicylate-5-sulfonamides containing active units as analgesic agents, J. Serb. Chem. Soc. 53(7):353-361 (1988).
Kenyon et al.,A model of angiogenesis in the mouse cornea, Invest. Ophthalmol. Vis. Sci., 37(8):1625-1632 (1996).
Knight et al.,A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metaoproteinases, FEBS Lett. 296(3):263-266 (1992).
McGeehan et al.,Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor, Nature, 370:558;561 (1994).
Mitchell et al.,Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage, J. Clin. Invest., 97(3):761-768 (1996).
Morphy et al.,Matrix metalloproteinase inhibitors: current status, Cur. Med. Chem. 2:743-762 (1995).
Rasmussen et al.,Matrix metalloproteinase inhibitor as a novel anticancer strategy: a review with special focus on batimastat and marimastat, Pharmacol. Ther., 75(1):69-75 (1997).
Reboul et al.,The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes, J. Clin. Invest., 97(9):2011-2019 (1996).
Schwartz et al.,Synthetic inhibitors of bacterial and mammalian interstitial collagenases, Prog. in Med. Chem., 29:271-334 (1992).
Barta Thomas E
Becker Daniel P
Bedell Louis J
DeCrescenzo Gary A
Freskos John N
Ashbrook Charles W.
Baude Eric J.
Chang Celia
G. D. Searle & Co.
LandOfFree
Sulfonyl aryl or heteroaryl hydroxamic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonyl aryl or heteroaryl hydroxamic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonyl aryl or heteroaryl hydroxamic acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695685